Panels
Health Policy Panel
Impact of Health Care Reform: Industry Response
Key questions to be addressed:
- What are the key aspects of reform that you would be most interested in seeing in the pending legislation?
- What aspects or reimbursement, like bundled payments, will impact your business model and how will you adapt?
- Given the planned coverage for the uninsured, what are the challenges you foresee to your firm?
- How can you provide and utilize additional data on your services or products to deliver the most value to patients and consumers?
Panelists:
- John (Jack) Bailey, Senior Vice President of Private, Public & Institutional Customers, GlaxoSmithKline
- Benjamin Breier, Executive Vice President & Hospital Division President, Kindred Healthcare
- Charles Cutler, Independent Consultant, Cutler Healthcare Consulting
- Jon Kaplan, Partner & Managing Director, The Boston Consulting Group
- Vadim Lubarsky, Director, Marwood Group
Pharma/Biotech Panel
What is the Next Business Model for the Pharma/Biotech Industry?
Key questions to be addressed:
- Given the drop in patented assets over the next few years, what strategic bets should firms make as to research (activities before proven efficacy) vs. development (activities after proven efficacy)?
- Is there a role for blockbuster drugs in the future business model of the pharma/biotech industry?
- How are emerging markets influencing your decision making in research and later stage development?
Panelists:
- Bill Anderson, Immunology & Ophthalmology Senior Vice President, Genentech
- Gary J. Kurtzman, Vice President & Managing Director in Life Sciences, Safeguard
- David Levy, Partner, Booz & Company
- C. David Nicolson, Senior Vice President of Worldwide Licensing & Knowledge Management, Merck & Co.
- Joshua Smiley, Vice President, CFO & LRL, Eli Lilly & Company
- Adam Woodrow, VP of Inflammation, Pfizer
Medical Devices Panel
Medical Device Models for Delivering Exceptional Value
Key questions to be addressed:
- How do you communicate the value of devices to providers, payers and patients?
- Are there ways to better rationalize costs to provide greater accessibility to devices?
- Can device combinations with pharma and IT offer novel methods for improving patient outcomes?
- How might health care reform provide opportunities and present challenges to device firms?
Panelists:
- Tom Hodson, Principal in the Life Sciences Industry, Deloitte Consulting LLP
- Jack Kelley III, Director of Strategic Marketing & Business Development in Pharmaceutical Systems, BD
- Suzanne McMonigle, Vice President of Marketing, Animas Corporation
- Brent Melancon, Vice President of Healthcare Systems, Medtronic
- David Nichols, Vice President of Product Development in Spine Division, Synthes
Finance Panel
Lessons Learned for the New Challenges Ahead
Key questions to be addressed:
- How could you have positioned yourself to take advantage of the opportunities in the last year? Has this changed as you look ahead to the next year?
- With the still sensitive market, what are the best methods for exit and how might these issues have changed your initial investment strategy?
- How did you incorporate health care reform in your investment decisions and how likely do you see implementation affecting your portfolio?
- A retrospective on the last three years: will things return to normal or are the fundamentals of the business truly different?
Panelists:
- Umber Ahmed, Partner, Platinum Gate Capital Management LLC
- Ron Eastman, Managing Director, Essex Woodlands Health Ventures
- James Forbes, Head Global Principal Investments, Bank of America
- Devin O’Reilly, Principal, Bain Capital
- Robert Schrepfer, Managing Director, Healthcare Value Capital
- Matthew P. Young, Managing Director, Global Healthcare Investment Banking, Barclays Capital
Venture Capital Panel
Life Science Venture Capital Investment Strategies in a Time of Reform
Key questions to be addressed:
- Which sectors and types of companies currently have investors’ attention and are receiving funding today?
- Given the valuation squeeze on investors, are VCs turning to alternative business models to adjust to the new environment?
- The genomics revolution was a major catalyst for life science VC. What is the next big thing that could pull health care venture capital out of the doldrums?
- From a deal-making perspective, what does a looming industry restructuring mean for life science venture capital?
Panelists:
- Darren Black, Partner, SV Life Sciences
- Brenda D. Gavin, Founding Partner, Quaker BioVentures
- Roger Longman, Former Managing Director, Elsevier Business Intelligence / Windhover Information
- Anupendra Sharma, Investment Partner, Siemens Venture Capital
- Steven St. Peter, Partner, MPM Capital
[
Go to Speakers >> ]
| Platinum Sponsor: |
Gold Sponsors: |
|
|
 |